Celcuity (CELC)
(Delayed Data from NSDQ)
$15.83 USD
+0.38 (2.46%)
Updated Oct 18, 2024 04:00 PM ET
After-Market: $15.95 +0.12 (0.76%) 7:58 PM ET
3-Hold of 5 3
D Value D Growth D Momentum D VGM
Brokerage Reports
0 items in cart
Celcuity, Inc. [CELC]
Reports for Purchase
Showing records 1 - 20 ( 28 total )
Company: Celcuity, Inc.
Industry: Medical - Biomedical and Genetics
Multiple Data Readouts in 2025; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S
Company: Celcuity, Inc.
Industry: Medical - Biomedical and Genetics
Gedatolisib Development on Track; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S
Company: Celcuity, Inc.
Industry: Medical - Biomedical and Genetics
All Eyes on VIKTORIA-1 Update in 2H24; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S
Company: Celcuity, Inc.
Industry: Medical - Biomedical and Genetics
Targeting Multiple Nodes of PAM Pathway With a Best-in-Class Inhibitor; Initiate With Buy and $27 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S
Company: Celcuity, Inc.
Industry: Medical - Biomedical and Genetics
Optimized Entry and Exit Levels for CELC 112123
Provider: Stock Traders Daily
Analyst: Research Department
Company: Celcuity, Inc.
Industry: Medical - Biomedical and Genetics
Company: Celcuity, Inc.
Industry: Medical - Biomedical and Genetics
Company: Celcuity, Inc.
Industry: Medical - Biomedical and Genetics
Company: Celcuity, Inc.
Industry: Medical - Biomedical and Genetics
AACR Presentations Showcase Gedatolisib; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHEN Y
Company: Celcuity, Inc.
Industry: Medical - Biomedical and Genetics
First-in-Class PI3K/mTOR Inhibitor In-Licensed; Reiterate Buy; Raising PT to $30
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHEN Y
Company: Celcuity, Inc.
Industry: Medical - Biomedical and Genetics
New Collaboration in Breast Cancer; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHEN Y
Company: Celcuity, Inc.
Industry: Medical - Biomedical and Genetics
Full-Year 2020 Financial Results Reported; Reiterate Buy; Raising PT to $19
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHEN Y
Company: Celcuity, Inc.
Industry: Medical - Biomedical and Genetics
New Pharma Collaboration in HER2-Negative Breast Cancer; Raising PT to $18
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHEN Y
Company: Celcuity, Inc.
Industry: Medical - Biomedical and Genetics
New Breast Cancer Clinical Collaboration Established; Raising PT to $14
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHEN Y
Company: Celcuity, Inc.
Industry: Medical - Biomedical and Genetics
Company: Celcuity, Inc.
Industry: Medical - Biomedical and Genetics
Company: Celcuity, Inc.
Industry: Medical - Biomedical and Genetics
CELsignia May Double the Targeted Cancer Therapies Market; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHEN Y
Company: Celcuity, Inc.
Industry: Medical - Biomedical and Genetics
CELsignia Pathway Activity Test for Ovarian Cancer Presented; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHEN Y
Company: Celcuity, Inc.
Industry: Medical - Biomedical and Genetics
1Q20 Financial Results Reported; Reiterate Buy; Reducing PT to $11
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHEN Y
Company: Celcuity, Inc.
Industry: Medical - Biomedical and Genetics
4Q and Full-Year 2019 Financial Results Reported; Reiterate Buy; Reducing PT to $19
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHEN Y